Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

• 1. 用于治疗去势抵抗性前列腺癌和成骨性骨转移的MET和VEGF的双重抑制剂 [P] . 中国专利： CN103402505A . 2013-11-20
• 2. 用于治疗去势抵抗性前列腺癌和成骨性骨转移的MET和VEGF的双重抑制剂 [P] . 中国专利： CN103391772A . 2013-11-13
• 3. - MET VEGF DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES [P] . 韩国专利： KR101882328B1 . 2018-07-27

  机译： -MET和VEGF的MET VEGF双重抑制剂用于治疗抗前列腺癌和成骨细胞转移瘤

• 4. DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES [P] . HUE045810T2 . 2020-01-28

  机译： MET和VEGF的双重抑制剂可治疗抗结直肠癌和成骨细胞转移瘤

• 5. DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES [P] . PL2621481T3 . 2020-03-31

  机译： MET和VEGF的双重抑制剂可治疗抗结直肠癌和成骨细胞转移瘤

• 1. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment [J] . Nathalie Bock, Ali Shokoohmand, Thomas Kryza, 骨研究（英文版） . 2019,第002期
• 2. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment [J] . Nathalie Bock, Ali Shokoohmand, Thomas Kryza, 骨研究：英文 . 2019,第002期
• 3. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer [J] . Mark N Stein, Neal Patel, Alexander Bershadskiy, 亚洲男性学杂志（英文版） . 2014,第003期
• 4. The metastatic castration-resistant prostate cancer treatment paradigm:more choices, more questions [J] . Evan Y Yu, William K Oh 亚洲男性学杂志（英文版） . 2014,第003期
• 5. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer [J] . MsaouelP., NandikollaG., PneumaticosS.G., Expert opinion on investigational drugs . 2013,第11期
• 6. Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option [J] . European journal of oncology nursing: the official journal of European Oncology Nursing Society . 2014,第Suppla1期
• 7. Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer [J] . D. Southcott, A. Awan, K. Ghate, Current oncology . 2020,第4期
• 8. Characterization of Bone Quality in Prostate Cancer Bone Metastases Using Raman Spectroscopy [C] . Xiaohong Bi, Chetan Patil, Colm Morrissey, Photonic therapeutics and diagnostics VI . 2010
• 9. Determination of novel metabolites of therapeutic agents used in the treatment of castration-resistant prostate cancer. [D] . Alyamani, Mohammad. 2017
• 10. MK591 a Second Generation Leukotriene Biosynthesis Inhibitor Prevents Invasion and Induces Apoptosis in the Bone-Invading C4-2B Human Prostate Cancer Cells: Implications for the Treatment of Castration-Resistant Bone-Metastatic Prostate Cancer [O] . Sivalokanathan Sarveswaran, Ritisha Ghosh, Shravan Morisetty, -1
• 11. MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer. [O] . Sivalokanathan Sarveswaran, Ritisha Ghosh, Shravan Morisetty, 2015
• 12. Dual-Action Armed Replicating Adenovirus for the Treatment of Osteoblastic Bone Metastases of Prostate Cancer. [R] . Douglas, J. T. 2007

• 1. Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 iin Vivo/i [J] . Thambi Dorai ,Janane Diouri ,Orla O’Shea . 癌症治疗（英文） . 2014,第4期
• 2. 去势抵抗性前列腺癌骨转移特点及其对化疗的预后作用 [C] . 罗波 ,崔殿生 ,魏少忠 . 第八届中国肿瘤学术大会暨第十三届海峡两岸肿瘤学术会议 . 2014
• 3. 来那度胺联合阿比特龙治疗骨转移去势抵抗性前列腺癌的疗效观察 [A] . 郭震 . 2020